The group will carry out work on a phase I study, it has also signed an expansion deal for a phase II clinical assessment, and it will deploy its expertise on an open-label extension phase III trial
IXICO said the new business builds on its expertise in the field of Alzheimer's and pointed out that it was in addition to the partnership with the Global Alzheimer's Platform announced in September.
In a statement, the company’s chief commercial officer, Lammert Albers, noted: "Today there are 50 million people worldwide that suffer with Alzheimer's and other forms of dementias.
“There are currently no means to prevent or delay onset, slow progression or meaningfully improve symptoms of Alzheimer's disease. With more than 120 unique investigational drugs in clinical trials, IXICO is proud to support some of these potential treatments that one day may be in the hands of Alzheimer's patients worldwide."